1	Definition of virological endpoints improving the design of HIV cure
2	strategies using analytical antiretroviral treatment interruption
3	
4	
5	Marie Alexandre ^{1,2‡} , Mélanie Prague ^{1,2‡} , Edouard Lhomme ^{1,2,5} , Jean-Daniel Lelievre ^{2,3} ,
6	Linda Wittkop ^{1,2,5} , Laura Richert ^{1,2,5} , Yves Lévy ^{2,3,4} , Rodolphe Thiébaut ^{1,2,5} *
7	
8	¹ University of Bordeaux, Department of Public Health, Inserm Bordeaux Population Health
9	Research Center, Inria SISTM, Bordeaux, France
10	² Vaccine Research Institute, Créteil, France
11	³ Inserm U955, Créteil, France
12	⁴ AP-HP, Hôpital Henri-Mondor Albert-Chenevier, Service d'Immunologie Clinique et Maladies
13	Infectieuses, Créteil, France
14	⁵ CHU Bordeaux, Department of Medical information, Bordeaux, France
15	
16	* <u>Corresponding author:</u>
17	Pr Rodolphe Thiébaut
18	Univ. Bordeaux, Inserm BPH, Inria SISTM
19	146 Rue Leo Saignat, 33076 Bordeaux
20	Email: rodolphe.thiebaut@u-bordeaux.fr
21	
22	[‡] These authors contributed equally to this work.
23	
24	
25	Reference count: 33 (/40)
26	
27	

28 Abstract

29

Background. Analytical treatment interruption (ATI) is the gold standard in HIV research to validate the ability of novel therapeutic strategies to long-term control viremia without antiretroviral treatment (ART). Viral setpoint is commonly used as endpoint to evaluate their efficacy. However, to mitigate higher viremia risk without ART, trials use short ATI phases and strict virological ART re-start criteria, compromising the observation of the setpoint.

Methods. We analyzed viral dynamics in 235 HIV-infected participants from three trials, examining various virological criteria during ATI phases. Time-related (e.g. time to rebound, peak and setpoint) and VL magnitude-related criteria (peak, setpoint and time-averaged AUC [nAUC]) were described. Spearman correlations were analyzed to identify surrogate endpoints for setpoints. Additional correlation analyzes were performed to identify optimal virological ART re-start criteria mitigating the risks of ART interruption and the evaluation of viral control.

Results. Comparison of virological criteria between trials showed strong dependencies on ATI design. Similar correlations were found across trials, with nAUC identified as the criterion most strongly correlated with the setpoint, with correlations higher than 0.70. A threshold of at least 100,000 copies/mL for two consecutive VL measurements is requested as virological ART re-start criteria to keep strong correlations between the setpoint and nAUC.

47 **Conclusions.** Our results emphasize the benefits of an ATI phase longer than 12 weeks, with 48 regular monitoring, and a VL threshold of 100,000 copies/mL as virological ART re-start 49 criteria to limit the risk for patients while capturing enough information to keep nAUC as an 50 optimal proxy for the setpoint.

51 *Keywords.* Analytical treatment interruption, clinical trials, antiretroviral treatment, HIV cure, 52 viral rebound, virological endpoint.

53 Introduction

Treatment interruption, i.e., discontinuation of antiretroviral treatment (ART), has been used in the evaluation of strategies aimed to save drug exposure (1–3). However, interruption of ART is associated to a higher risk for clinical progression (4). Nevertheless, treatment interruption remains the only means to evaluate therapeutic interventions such as immunotherapies or therapeutic vaccines (5) aimed to control HIV replication without ART (6–11).

60 While accepted in a context of clinical trials involving people living with HIV (PLWH) (12,13), 61 treatment interruption should be carefully monitored and several recommendations have 62 been proposed to limit potential risks, in terms of morbidity, mortality, disease progression, 63 HIV transmission, emergence of new drug-resistance, development of neurological or 64 cardiovascular disorders (14,15). These recommendations led to the development of clearly-65 defined interruptions: Analytical treatment interruptions (ATI) (14). Therefore, it is of the 66 upmost importance to optimize the design of ATI trials to provide a maximum information 67 with a minimum risk exposure (16). Stringent ART re-start criteria upon viral rebound are 68 included in research protocols while virological endpoints to assess efficacy of experimental 69 strategies have been largely discussed (14,16–20). Two types of criteria are usually 70 considered in the definition of virological endpoints, each leading to a distinct design of the 71 ATI phase: the time to viral rebound and the setpoint, that is the relatively stable level of HIV 72 viral load (VL) after the rebound (14,21). When the outcome of interest is the time to viral 73 rebound, the threshold of VL for ART re-start is often set at a low level to limit risks (e.g. 1 74 000 copies/mL). Optimal designs have been recently proposed for studies using "time to viral 75 rebound" as endpoints (16). One drawback here could be the ART re-start at a low viral 76 rebound which impair the evaluation of viral replication control. On the other hand, studies 77 using "setpoint" as endpoint require longer treatment interruption periods with higher 78 thresholds for ART re-start, leading to a potential increased risk of HIV transmission and side 79 effects. Thus, while the "time to rebound" could be easily determined in ATI studies, 80 assessing the setpoint of viral replication, a proxy of the control of viral rebound, remains 81 challenging. Therefore, the need to define optimal designs of ATI phase for "setpoint" 82 studies, mitigating the risks related to treatment interruption and the evaluation of viral 83 control, is essential.

In the present study, we analyzed several virological parameters of the kinetics of viral rebound following ATI in various clinical trials of immunotherapeutics in chronic PLWH. The objective was to identify at earliest phase of ATI potential surrogate endpoints predictive of viral setpoints. These results might have a practical impact on the design of future clinical trials with ATI.

89 Materials and Methods

90 Clinical trial data

91 We considered individual data extracted from three distinct trials in PLWH including two 92 therapeutic vaccine trials and one testing an IL-2 immunotherapeutic strategy. All trials 93 comprised an ATI phase to evaluate the virological efficacy of these strategies in maintaining 94 low viral replication after ART interruption (**Figure 1**).

95 The VRIO2 ANRS 149 LIGHT trial (22) (NCT01492985, and labelled LIGHT) was a multicenter,

96 double-blind, placebo-controlled, randomized, Phase II trial evaluating the safety,

97 immunogenicity and virological efficacy of a prime-boost vaccine strategy, using recombinant

98 DNA vaccine GTU-MultiHIV B as prime, and lipopeptide vaccine HIV-LIPO-5 as boost.

99 The ANRS/VRI DALIA trial (23–25) (NCT00796770, and labelled DALIA) was a single-center,
100 single arm Phase I trial evaluating the safety of a dendritic cell vaccine.

101 The ANRS 118 ILIADE trial (26) (NCT00071890, and labelled ILIADE) was a multicenter, open-102 label, placebo-controlled, randomized Phase II/III trial evaluating the efficacy of IL-2 103 immunotherapy to extend the period of time off ART, defined by three cycles of 104 subcutaneous injections of recombinant IL-.

105 In LIGHT, 103 ART-treated HIV-infected patients were randomized in a 2:1 ratio to receive 106 their ART in combination with either an active vaccine or placebo. From week 36 to 48, 107 patients interrupted their ART and were regularly monitored with immunological (CD4+ and 108 CD8+ T cell counts) and VL measurements performed every 2 weeks (**Figure 1A**). The primary 109 virological endpoint studied was the maximum observed VL (in log₁₀ copies/mL) during ATI 110 phase.

In DALIA, 19 ART-treated HIV-infected patients were included who interrupted ART for 24
weeks, from week 24 to 48, and were monitored every 1 to 4 weeks (Figure 1C). No
virological endpoint was evaluated in this study.

Finally, ILIADE enrolled 148 ART-treated HIV-infected patients randomized in a 1:1 ratio to receive ART either in combination with IL-2 therapy or alone. From week 24 to 72, ART was

5

- interrupted and CD4+, CD8+T cells counts and VL were collected every 8 weeks (Figure 1B).
- 117 No virological endpoint was considered in ILIADE.
- 118 The reader can refer to **Figure 1** for the list of criteria leading to ART re-start before the end
- 119 of the protocol-defined ATI phase.

120 Ethics statement

121 The protocol of LIGHT study was approved by the ethics committee of Ile de France 5 (Paris-122 Saint-Antoine) and authorized by the French regulatory authority (ANSM). The DALIA study 123 was sponsored by the Baylor Institute for Immunology Research and the Agence Nationale de Recherches sur le SIDA et les hepatites (INSERM ANRS), and the protocol was approved by 124 125 the IRB of Baylor Research Institute (BRI). The protocol of ILIADE study was approved by the 126 ethics committee of the Hospital Henri Mondor and the National Institute of Allergy and 127 Infectious Diseases (NIAID). All participants provided written informed consent before 128 participation.

129 **Definition of virological criteria**

Virological data of the trials described above were analyzed in the present study, and a total of eight criteria summarizing the dynamics of viral rebound during ATI were considered. To account for the differences of design of ATI phases between the three trials (e.g., ATI phase duration or sampling frequencies, virological criteria were divided into two categories: (1) fixed criteria if they were principally related to the magnitude of VL and, (2) temporal criteria if they corresponded to time-related outcomes.

- 136 The three fixed criteria included in this analysis were (1) peak VL, (2) setpoint and, (3) time-137 averaged area under the curve (AUC) (i.e., AUC divided by the duration of ATI phase, labelled 138 nAUC). A normalized version of AUC was used to adjust for ATI duration and to be 139 comparable between patients. In the absence of a formal definition of the setpoint in the literature, the steady state of VL reached after the peak VL was defined as the mean of 140 141 observations included in a sliding window of height 0.5 \log_{10} copies/mL, with a width of at 142 least 4 weeks and including at least two VL values (17). Moreover, the assumption that the 143 setpoint was correctly measurable in the different trials was made.
- 144 The temporal criteria were (1) time to rebound (TTR), (2) slope of viral rebound, (3) time to 145 peak VL, (4) time to setpoint, (5) time to distinct VL thresholds (i.e., 200, 1 000, 10 000 and

146 100 000 copies/mL). The reader can refer to Table 1 and Figure 2A for a full definition of147 these criteria

148 Identification of the optimal virological criterion to be used as primary endpoint

We sought to identify optimal criterion summarizing viral dynamics that could be used as proxy for the setpoint, based on the following characteristics: highly associated with the setpoint, and whose observation is less impacted by the duration of ATI phase.

152 Individual viral dynamics can be impacted by both the effect of the intervention and the 153 design of ATI phase. In each trial, the design of ATI being comparable between the two 154 groups of treatment, we first performed a descriptive analysis and a comparison of the two 155 groups at each time point to identify potential differences of dynamics, induced by treatment 156 effect, that could impact the values of virological criteria. As no statistical differences were 157 identified between groups, whether in LIGHT or ILIADE and whatever the time point, the two 158 groups were pooled together in each trial to increase statistical power. The following analyses were then performed at trial level (i.e., LIGHT Vs ILIADE Vs DALIA). Secondly, once 159 the eleven aforementioned virological criteria estimated for each individual, a descriptive 160 161 and comparison analysis between trials were performed to analyze how ATI designs 162 impacted their values. Finally, Spearman correlations were evaluated between criteria and 163 compared between trials to (1) see how ATI designs impact correlation patterns, and (2) 164 identify criterion the most associated to the setpoint.

In this analysis, patients were excluded if they fulfilled one of the following criteria: ATI not initiated, detectable VL at the time of ART interruption (condition for ATI initiation), therapeutic strategy not received (e.g., at least one IL-2 dose requested in ILIADE). Moreover, only the first 48 weeks of ATI (i.e., until the primary outcome at week 72, see Figure 1B) were included in ILIADE, to limit heterogeneity among trials.

Assessment of the choice of virological restart ART criteria on the evaluation of the virological endpoint

To limit the risks for participants during ATI phase, ART re-start criteria are defined in protocols. These criteria define conditions under which it is vital for a patient to re-start ART before the end of ATI phase. While the patient remains in the trial and is still frequently monitored after ART re-start to ensure its safety and to contribute to other endpoints, this

176 one does not fulfill conditions to contribute to virological endpoint. Consequently, censoring 177 of follow-up is considered due to strategy discontinuation and virological measurements collected from that point are treated as monotonic missingness (once missing, always 178 179 missing subsequently) for the evaluation of virological criteria. Although ART re-start criteria 180 can have a strong impact on primary outcomes and, by extension, on the evaluation of 181 vaccine efficacy, no real consensus has been reached about their definition (14). In this work, 182 we focused on virological ART re-start criteria defined as VL threshold above which patients have to re-start ART for their safety, named VL upper-threshold thereafter. As shown in 183 184 Figure 2B, censored follow-up, resulting from the use of VL upper-threshold, required the 185 study of right-censored viral dynamics.

186 We re-analyzed the three trials by investigating the impact of VL upper-thresholds on the association between the setpoint and nAUC. Three commonly considered VL upper-187 188 thresholds were investigated: (1) 10 000 copies/mL, (2) 50 000 copies/mL, and (3) 100 000 189 copies/mL. To this end, Spearman correlations were studied between the setpoint, estimated 190 on complete data (i.e., not impacted by VL upper-threshold), and the nAUC calculated on right-censored viral dynamics, labelled right-censored nAUC (Figure 2B). Moreover, we 191 192 investigated the need for a confirmation measure before any ART restart. To this end, correlations between the setpoint and the nAUC were evaluated considering censoring of 193 194 follow-up either 1) as soon as VL upper-threshold has been exceeded for one viral measure 195 (i.e., without confirmation measure), or 2) once VL upper-threshold has been exceed for two 196 consecutive viral measures (i.e., with confirmation measure).

197 Statistical analysis

198 All analyses were performed in R (version 4.2.1). Continuous variables were expressed in 199 median (interquartile [IQR]), and discrete variables in absolute number and percentage. The 200 Student t-test was used to compare VL measurements between groups. The non-parametric 201 Mann-Whitney U and Kruskal-Wallis tests were used to perform pairwise comparisons and 202 multiple group comparisons of virological criteria, respectively. The associations between 203 virological criteria in each trial were evaluated using Spearman correlations. Statistical 204 significance was defined as a p-value lower than 0.05, after Benjamini and Hochberg false 205 discovery rate-adjustment (27) for multiple testing.

206 **Results**

207 **Population**

A total of 235 patients, out of the 270 enrolled in the three trials, were included in the

- present study: 87 in LIGHT (n=31 in placebo group and n=56 in vaccine group), 129 in ILIADE
- 210 (n=57 in control group and n=72 in IL-2 group) and 19 in DALIA (Figure S1).

211 **Description of virological measurements**

Viral rebound dynamics for the three trials are shown in **Figure 3**, and distributions of VL measured at each sampling time point during ATI phase are summarized in **Table S1**. The median length of follow-up before ART re-start ranged from 12 to 48 weeks, with a median number of VL measurements from 6 to 11 (**Table 2**). The percentages of patients prematurely reinitiating their ART before the end of ATI phase were equal to 21 % in LIGHT (23% for Placebo and 20% for vaccinated), 26% in ILIADE (35% for Control and 19% for IL-2), and 16% in DALIA.

219 Comparisons, at the different time of measurements, between VL values collected in the 220 experimental and the control group highlighted similar viral, whether in LIGHT (p-values >221 (0.43) or in ILIADE (p-values > 0.53) (see **Table S1**). Groups were then pooled in each trial to 222 increase the statistical power. As shown in Figure 4, no significant difference was observed 223 between the different trials from week 8 (p-value > 0.28). However, viral dynamics differed 224 across trials during the earliest phase of ATI. Mean VL measured in DALIA were significantly 225 lower than in LIGHT at weeks 2 and 4 (2.05 vs 2.49 log10 copies/mL at week 2, p-value=0.04; 226 3.26 vs 4.12 log₁₀ copies/mL at week 4, p-value=0.04). 227 Despite the absence of strong differences in the dynamics of viral rebound between trials,

228 the duration of ATI phase, sampling frequencies and intervals differ between trials, and 229 consequently can impact values of virological criteria.

230 Assessment of different virological criteria definitions

The virological criteria describing dynamics of viral rebound calculated in the different groups are summarized in **Table 3**. No statistical differences were found between groups in LIGHT (Placebo vs Vaccine) and ILIADE (Control vs IL-2), allowing an analysis at trial level in the following results (**Figure 5**).

235 Fixed criteria

No statistical differences of setpoints were observed between trials with mean values ranged from 4.23 in DALIA to 4.42 log₁₀ copies/mL in LIGHT (p-value=0.39) (**Figure 5B**). This result was in accordance with the absence of significant differences of VL measurements beyond week 4. Despite this homogeneity among trials, a lower percentage of patients reached the setpoint during ATI in LIGHT (54%) compared to both DALIA (95%) and ILIADE (86%). This difference can be explained by the shorter ATI phase of only 12 weeks in LIGHT, making its observation more difficult.

243 Both the peak VL and the nAUC were significantly different between LIGHT and ILIADE, 244 whereas no differences were observed between DALIA and LIGHT, DALIA and ILIADE. As 245 shown in **Figure 5A** and **Figure 5C**, the mean peak VL was significantly higher in LIGHT than in 246 ILIADE (+ 6%, p-value <0.001), while the mean nAUC was significantly lower in LIGHT than in 247 ILIADE (- 8%, p-value <0.01). Though not a direct time-dependent criteria, the lower peak VL 248 in ILIADE can be explained by its study design: the longer the time-interval between two VL 249 measurements (every 8 weeks in ILIADE instead of 2 weeks in LIGHT), the higher the 250 probability to miss the peak and capture a measure in the decreasing dynamic following the 251 peak (see Figure S3 for an illustration).

252 Time-dependent criteria

253 The analysis of time-dependent criteria highlighted their strong dependence on study design, 254 i.e. ATI duration and sampling intervals. As shown in Table 3 and Figure 5 D-F, with VL 255 measurements collected every 8 weeks, ILIADE's patients showed significantly different 256 results than those included in LIGHT and DALIA. In particular, they were characterized by a 257 significantly higher mean TTR and time to setpoint (TTR: 8.64 vs 3.04 and 4.47 weeks, 258 respectively, p-values < 0.001; time to setpoint: 15.9 vs 6.43 and 10.9 weeks, respectively, p-259 values <0.001). In contrast, a significantly lower mean slope of rebound was observed in 260 ILIADE than in both LIGHT and DALIA (-69% and -62%, respectively, p-value <0.0001). These 261 variations mostly result from the higher TTR. Except for barely significant lower mean time to 262 setpoint between LIGHT and DALIA (6.43 vs 10.9 weeks, p-value < 0.05), explained by the 263 difference of ATI duration, similar temporal endpoints were observed in these two trials.

264 Analysis of correlations between virological criteria.

265 To identify virological criteria summarizing viral rebound and highly associated with the 266 setpoint, we performed correlation analysis between the virological criteria. Figure 6 267 displayed Spearman correlations between the five virological criteria the most used obtained 268 in the three trials (see Figure S4 for correlations between the eleven virological criteria 269 defined in this analysis, and Figure S5 for Pearson correlations and scatter plots). Similar 270 patterns of correlations were obtained between the different trials. First, the absence of 271 significant correlations between the TTR and the setpoint, the two virological endpoints the 272 most widely recommended to assess vaccine efficacy in HIV therapeutic clinical trials (14). 273 Second, we identified strong significant positive correlations between the setpoint and both 274 the peak VL and the nAUC (p-values < 0.001), with higher correlation coefficients for the 275 nAUC (0.70 vs 0.61 in LIGHT, 0.90 for both in ILIADE, and 0.75 vs 0.73 in DALIA). The 276 correlations between TTR and other endpoints were less consistent across trials. For 277 instance, a negative correlation between the TTR and the nAUC was found in LIGHT (-0.57, p-278 value <0.0001) but not in DALIA and ILIADE.

These results allowed to identify the nAUC as the virological criteria the most strongly correlated with the setpoint, and which can be evaluated regardless the design of the ATI phase. However, it was worth noting that the strongest correlations between these two criteria were observed in ILIADE rather than in LIGHT, indicating that this association seems influenced by the duration of ATI phase.

Virological restart criteria impact the association between the setpoint and the nAUC.

286 We assessed the impact of ART re-start criteria, defined as VL upper-threshold (see Figure 287 2B), on the correlation between the setpoint and the nAUC. Figure 7 illustrated the Spearman correlations between the setpoint and the right-censored nAUC for different 288 289 values of the VL upper-threshold (whether for discrete values in Figure 7A or continuous 290 values in Figures 7B-D), with or without considering a confirmation measure before 291 censoring follow-up. In most cases, the higher the VL upper-threshold, the more significant 292 and stronger the correlation coefficient. Moreover, results obtained in both LIGHT and DALIA 293 highlighted the benefit of considering a confirmation measure to retrieve the significance of 294 correlations. While no significant correlations were identified in these two trials in absence

295 of confirmation measure, positive significant correlations were identified when an additional 296 VL measure was considered with a VL threshold of 100 000 cp/mL. The use of a low 297 threshold to censure data can lead to non-conclusive results (non-significant and weak 298 correlation coefficients), or even lead to wrong conclusion about vaccine efficacy. As example, an inversion of the sign of correlations was observed for intermediate VL upper-299 300 threshold without confirmation measure, between 3.5 and 4.8 \log_{10} copies/mL in DALIA and 301 between 4.0 and 4.5 log₁₀ copies/mL in LIGHT. The use of a VL upper-threshold of at least 302 100 000 copies/mL with a confirmation measure allowed to retrieve at least 50% of the 303 magnitude of the correlation between the setpoint and nAUC estimated on complete data 304 (LIGHT: 50%, ILIADE: 94%, DALIA: 83%).

305 Discussion

306 This analysis of virological criteria in three different ATI clinical trials showed that the design 307 of ATI phase and the definition of the virological endpoints are crucial for the evaluation of 308 HIV cure strategies. When comparing the different virological criteria between the ATI trials, 309 we found that especially the results of time-dependent virological criteria varied according to 310 the design of ATI phase, i.e. ATI duration, sampling frequencies and intervals between viral 311 load measurements. Our study identified the nAUC as the virological criteria the most 312 strongly correlated with the setpoint. It has to be noted that, unlike the setpoint, the nAUC 313 can be observed regardless of the design of ATI phase. Furthermore, we showed that the use 314 of a too conservative threshold for virological ART re-start criterion can induce an increasing 315 risk of missing important effects of the immune intervention on viral control. However, the 316 use of a high value, i.e. 100 000 copies/mL reinforces the value of nAUC as a valid proxy of 317 the setpoint. In particular, if the interest is in the post-replication control of infection, 318 through the so-called setpoint studies (16), we showed that the nAUC is a valuable endpoint 319 even in case of censored follow-up (28). Our results of correlations between virological 320 criteria were consistent with those reported in other trials (17). The absence of correlation 321 between time to rebound and setpoint has already been reported in other studies such as in 322 the pooled analysis of 6 ACTG trials (19). Biologically, this could be explained by the fact that 323 the initiation of the viral replication and the control of it afterwards are driven by different 324 biological mechanisms. A recall T cell response stimulated by the start of the viral replication 325 is potentially responsible for post-replication control (3,29). Hence, the pre-ART viral load is 326 more correlated to the viral setpoint (19) than the time to rebound. Consequently, this 327 absence of correlation emphases the necessity of choosing the most accurate and relevant 328 primary endpoints that is in accordance with the objective of the trial. In the present work, it 329 is also interesting to point out that the viral slope is also weakly correlated with the viral 330 setpoint, suggesting that the secondary immune response is playing a bigger role on the 331 control of viral replication after the peak as it is observed during primary infection.

This study is based on three clinical trials and thus the generalizability of our result may be limited. However, the information brought by real observed data from existing clinical trials helps to go beyond simulations (16) and the results were consistent with results reported in other additional trials (17,19). When the intervention and its expected impact is based on

13

other mechanism than active immune control of viral replication such as passive
immunization through neutralizing antibodies (Sneller et al. Science Trans Med 2019) then
other endpoints and designs should be considered.

The statistical requirement that ART should not be re-initiated before confirmed viral load of more than 100 000 copies/mL is in agreement with what is recommended when the interest is in the viral setpoint (14). This does not preclude to consider all additional criteria (clinical and CD4 count) for patients' safety. Specific statistical approaches have been developed to take into account incomplete information in such context (28).

344 Beyond statistical and clinical considerations, patient's perception should be taken into 345 account and recent studies have shown the good acceptability of ATI trials (12,13,30) as long 346 as severe side effects are avoided (31). According to these studies, a part of the respondents 347 would not accept any sustained period of viremia (35% in (32)). This would potentially 348 restrict the inclusion rate in the trials. Also, the preferred frequency of biological 349 measurements and clinical monitoring during ATI was monthly (32). Biotechnological 350 improvements making measurements at home feasible could help coping with this patient's 351 preference (33).

352 Key recommendations for future HIV therapeutic trials with ATI evaluating the 353 ability of a treatment to control viral replication in the absence of ART

354 Results provided by this work allowed us to make some recommendations. First, the time-355 averaged area under the viral rebound curve during the ATI phase (nAUC here) has been 356 shown to be the optimal virological criterion to use as proxy to the setpoint and 357 consequently as primary virological endpoint. Secondly, the optimal design of ATI phase 358 allowing a good balance between minimization of the risk for patients and the maximization 359 of the capacity to evaluate the effect of intervention on viral dynamics includes (1) a duration 360 of the ATI phase of more than 12 weeks and no longer than 24 weeks to ensure patients 361 safety, (2) regular monitoring during the early phase of the viral rebound dynamics, with viral 362 load measurements every 1 to 2 weeks until reaching the setpoint (i.e., around week 12), 363 and (3) viral load measurements every 2 to 4 weeks thereafter. Finally, the use of the VL 364 upper-threshold of 100 000 copies/mL as virological ART re-start criteria appears as the best 365 trade-off limit the risk for patients and capture enough information to keep nAUC as a good

366 proxy of the setpoint. These results and proposals could help to optimize the design of 367 clinical trials testing HIV cure strategies.

368

369 **Contributions**

Y.L., M.P., and R.T. conceptualized the study. M.A. accessed and verified data, and conducted
the formal analysis. M.P. and R.T. supervised the analysis. All authors contributed to data
interpretation. M.A created the first draft of the figures, and M.A. and R.T. wrote the first
draft of the manuscript. All authors critically revised and edited the manuscript and
approved the final version for submission.

375

376 Funding

This work was supported by the Investissements d'Avenir program managed by the ANR under reference ANR-10-LABX-77-01 (VRI - Vaccine Research Institute) and by the European Union's Horizon 2020 research and innovation program under grant agreement No. 681032 (EHVA).

381

382 **Data availability**

The data that support the findings of this study are available from the corresponding author,R.T. upon reasonable request.

385

386 **Conflicts of interests**

387 The authors declare no competing interests.

388

389

390 Legend of Figures

Figure 1 – Study designs of HIV therapeutic vaccine trials. (A) LIGHT trial. Participants received a prime-boost vaccine strategy, using recombinant DNA vaccine GTU-MultiHIV B or placebo as prime (3 doses at weeks 0, 4 and 12), and lipopeptide vaccine HIV-LIPO-5 or placebo as boost (2 doses at weeks 20 and 24). (B) ILIADE trial. Participants an IL-2 immunotherapy, defined by three cycles of

15

395 subcutaneous injections of recombinant IL-2 (2 injections of 6x10⁶ international units (IU) per day for 396 5 days, at weeks 0, 8 and 16), or placebo. (C) DALIA trial. Participants received 4 doses of a dendritic 397 cell vaccine, at weeks 0, 4, 8 and 12 weeks. (A-C) In the three trials, patient could prematurely re-398 start ART during the protocol-defined ATI phase if they met the following criteria: (1) wish of patients 399 or of their doctors, (2) CD4+ T-cell count dropped below 350 cells/µL at two consecutive 400 measurements 2-weeks apart, and (3) occurrence of an opportunistic infection or a serious non-AIDS 401 defining event. In DALIA, a drop of CD4+ T-cell count below 25% of total lymphocytes for two 402 consecutive measurements was also considered. Analysis performed in this paper focused exclusively 403 on viral load data collected during ATI phase (i.e., free-of-ART phase). In ILIADE and DALIA, only data 404 collected from ART interruption to the time of primary endpoint (colored in orange, W72 and W48, 405 respectively) were considered.

406 Figure 2 – Graphical representation of virological criteria analyzed in the study. Black and white dots 407 represent detectable and undetectable viral load measurement collected during ATI phase, 408 respectively, and gray dots those collected after ART re-start. The horizontal gray dotted line 409 represent the limit of detection. (A) Virological criteria describing viral rebound dynamics. (B) 410 Virological restart ART criteria inducing strategy discontinuation and censoring of follow-up. Orange 411 dot shows the first viral load measure exceeding the VL upper-threshold represented by the 412 horizontal red dashed line (i.e., time at which viral dynamic is censored when no confirmation 413 measure is considered before ART re-start). Red dot shows the viral load measure at which viral 414 dynamic is censored when a confirmation measure is required before any ART resumption. Gray 415 crosses display viral load measures unobserved due to censoring of following after strategy 416 discontinuation.

Abbreviations: ART, antiretroviral treatment; TTR, time to rebound; TTsetpoint, time to setpoint;
TTPeak, time to VL Peak; AUC, area under the curve; VL, viral load.

419 Figure 3 – Viral dynamics observed in the three trials in ATI phase. (A) Viral dynamics observed during 12-week ATI phase in LIGHT trial, with monitoring every 2 weeks. (B) Viral dynamics observed 420 421 during 48-week ATI period in ILIADE trial, with monitoring every 8 weeks. (C) Viral dynamics observed 422 during 36-week ATI period in DALIA trial, with monitoring every 1 to 4 weeks. (A-C) Thick and thin 423 lines represent the median and individual dynamics, respectively, and error bars represent 424 interguartile ranges. Solid and dashed lines correspond to dynamics in therapeutic and 425 control/placebo groups, respectively. Grey areas highlight limits of detection (i.e., 40 cp/mL for LIGHT, 426 and 50 cp/mL for ILIADE and DALIA). Red dotted vertical lines for represents the end of ATI phase 427 (week 12 in LIGHT and week 36 in DALIA).

428 Figure 4 – Distribution of viral load measurements collected during ATI phase in the three trials at

429 **common time points** (LIGHT in blue, ILIADE in green, and DALIA in pink). Brackets show significant p-430 values after multiplicity adjustment: *: $p \le 0.05$, **: $p \le 0.01$, ***: $p \le 0.001$, ****: $p \le 0.0001$.

431 Figure 5 – Distribution of different virological criteria within each trial. Blue thick brackets below 432 boxplots and black thin brackets above boxplots show significant p-values of the multiple group 433 comparisons (Kruskal-Wallis test) and pairwise comparisons (Mann-Whitney U test), respectively. 434 Significant p-values after multiplicity adjustment: *: $p \le 0.05$, **: $p \le 0.01$, ***: $p \le 0.001$, ****: $p \le 0.001$, ***: $p \le 0.001$, **: $p \ge 0.001$, **: $p \ge 0.001$, **: $p \le 0.001$, **: $p \ge 0.001$, *: 435 0.0001. (A) Distribution of the peak VL, in \log_{10} cp/mL. (B) Distribution of the setpoint, in \log_{10} cp/mL. 436 (C) Distribution of the time-averaged AUC (nAUC), in \log_{10} cp/mL. (D) Distribution of the time to 437 rebound, in weeks. (E) Distribution of the slope of the viral rebound, in log₁₀ cp/mL/week. (F) 438 Distribution of the time to setpoint, in weeks. (G) Distribution of the time to peak of VL, in weeks. (H) 439 Time to 200 copies/mL of VL, in weeks. (I) Time to 1 000 copies/mL of VL, in weeks. (J) Time to 10 000 440 copies/mL of VL, in weeks. (K) Time to 100 000 copies/mL of VL, in weeks. Abbreviations: nAUC, 441 time-averaged area under the curve ; VL, viral load.

Figure 6 – Heatmap of pairwise Spearman correlations between the five main virological criteria in the three clinical studies. (A) LIGHT clinical trial (n=87). (B) ILIADE clinical trial (n=129). (C) DALIA clinical trial (n=19). (A-C) Correlations higher than 0.5 are colored in orange-red palette and correlations lower than -0.5 in blue palette. P-values adjusted for multiplicity testing are indicated in brackets: *: $p \le 0.05$, **: $p \le 0.01$, ***: $p \le 0.001$, ****: $p \le 0.0001$. Abbreviations: nAUC, timeaveraged area under the curve; TTR: time to rebound.

448 Figure 7 – Spearman correlations between the setpoint and nAUC calculated on right-censored viral 449 dynamics according to VL upper-thresholds. (A) Heatmap of Sperman correlations in each trial (y-450 axis) between the setpoint and nAUC, whether with or without censoring of follow-up, and with or 451 without consideration of a confirmation measure before premature ART restart. Three commonly 452 used VL upper-thresholds are considered: 10 000 cp/mL, 50 000 cp/mL and 100 000 cp/mL. 453 Significant positive and negative correlations are highlighted in red and blue, respectively. (B-D) 454 Analysis of Spearman correlations between the setpoint estimated on complete virological data, and 455 the nAUC estimated on right-censored viral dynamics. The x-axis represents the VL upper-thresholds 456 above which censoring of follow-up was considered. The y-axis represents the value of the 457 correlation coefficient between the setpoint and the right-censored nAUC. Solid and dashed lines 458 represent the results with or without a confirmation measure in the calculation of the right-censored 459 nAUC, respectively. Yellow symbols (circles and triangles for with or without confirmation, 460 respectively) highlight significant correlations (adjusted p-value ≤ 0.05). The horizontal gray dotted

- 461 line represents the transition between positive and negative correlations. The horizontal red solid line
- 462 represents the value of the correlation coefficient between the setpoint and the nAUC estimated on
- 463 complete data. (B) LIGHT trial. (C) ILIADE trial. (D) DALIA trial.

464 **References**

- Davey RTJ, Bhat N, Yoder C, Chun TW, Metcalf J, Dewar R, et al. HIV-1 and T cell dynamics after
 interruption of highly active antiretroviral therapy (HAART) in patients with a history of sustained
 viral suppression. 1999;6.
- Ortiz GM, Wellons M, Brancato J, Vo HTT, Zinn RL, Clarkson DE, et al. Structured antiretroviral treatment interruptions in chronically HIV-1-infected subjects. Proceedings of the National Academy of Sciences. 6 nov 2001;98(23):13288293.
- 3. Oxenius A, Price DA, Günthard HF, Dawson SJ, Fagard C, Perrin L, et al. Stimulation of HIV-specific
 cellular immunity by structured treatment interruption fails to enhance viral control in chronic
 HIV infection. Proceedings of the National Academy of Sciences. 15 oct 2002;99(21):13747 252.
- 474 4. Strategies for Management of Antiretroviral Therapy (SMART) Study Group, El-Sadr WM,
 475 Lundgren JD, Neaton JD, Gordin F, Abrams D, et al. CD4+ count-guided interruption of
 476 antiretroviral treatment. N Engl J Med. 30 nov 2006;355(22):2283296.
- 5. Deeks SG, Archin N, Cannon P, Collins S, Jones RB, de Jong MAWP, et al. Research priorities for an
 HIV cure: International AIDS Society Global Scientific Strategy 2021. Nat Med. déc
 2021;27(12):2085 298.
- Gunst JD, Højen JF, Pahus MH, Rosás-Umbert M, Stiksrud B, McMahon JH, et al. Impact of a TLR9
 agonist and broadly neutralizing antibodies on HIV-1 persistence: the randomized phase 2a TITAN
 trial. Nat Med. oct 2023;29(10):2547258.
- Julg B, Stephenson KE, Wagh K, Tan SC, Zash R, Walsh S, et al. Safety and antiviral activity of triple
 combination broadly neutralizing monoclonal antibody therapy against HIV-1: a phase 1 clinical
 trial. Nat Med. juin 2022;28(6):1288 296.
- Lee MJ, Collins S, Babalis D, Johnson N, Falaschetti E, Prevost AT, et al. The RIO trial: rationale, design, and the role of community involvement in a randomised placebo-controlled trial of antiretroviral therapy plus dual long-acting HIV-specific broadly neutralising antibodies (bNAbs) in participants diagnosed with recent HIV infection—study protocol for a two-stage randomised phase II trial. Trials. 5 avr 2022;23(1):263.
- 491 9. Sneller MC, Justement JS, Gittens KR, Petrone ME, Clarridge KE, Proschan MA, et al. A
 492 randomized controlled safety/efficacy trial of therapeutic vaccination in HIV-infected individuals
 493 who initiated antiretroviral therapy early in infection. 2017;11.
- 10. Trkola A, Moore PL. Vaccinating people living with HIV: a fast track to preventive and therapeutic
 HIV vaccines. The Lancet Infectious Diseases [Internet]. 23 oct 2023 [cité 9 nov 2023];0(0).
 Disponible sur: https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(23)004814/fulltext
- 498 11. Wen Y, Bar KJ, Li JZ. Lessons learned from HIV antiretroviral treatment interruption trials. Current
 499 Opinion in HIV and AIDS. sept 2018;13(5):416.
- Dubé K, Agarwal H, Stockman JK, Auerbach JD, Sauceda JA, Conroy AA, et al. "I Would Absolutely
 Need to Know That My Partner Is Still Going to be Protected": Perceptions of HIV Cure-Related
 Research Among Diverse HIV Serodifferent Couples in the United States. AIDS Research and
 Human Retroviruses. août 2023;39(8):400213.


13. Neergaard R, Jones NL, Roebuck C, Rendle KA, Barbati Z, Peterson B, et al. "I Know That I Was a
Part of Making a Difference": Participant Motivations for Joining a Cure-Directed HIV Trial with an
Analytical Treatment Interruption. AIDS Research and Human Retroviruses. août
2023;39(8):414221.


- Julg B, Dee L, Ananworanich J, Barouch DH, Bar K, Caskey M, et al. Recommendations for
 analytical antiretroviral treatment interruptions in HIV research trials—report of a consensus
 meeting. The Lancet HIV. 1 avr 2019;6(4):e259268.
- Leal L, Fehér C, Richart V, Torres B, García F. Antiretroviral Therapy Interruption (ATI) in HIV-1
 Infected Patients Participating in Therapeutic Vaccine Trials: Surrogate Markers of Virological
 Response. Vaccines (Basel). 5 août 2020;8(3):442.
- Lau JSY, Cromer D, Pinkevych M, Lewin SR, Rasmussen TA, McMahon JH, et al. Balancing
 Statistical Power and Risk in HIV Cure Clinical Trial Design. The Journal of Infectious Diseases. 15
 juill 2022;226(2):236245.
- 517 17. Fehér C, Leal L, Plana M, Climent N, Crespo Guardo A, Martínez E, et al. Virological Outcome
 518 Measures During Analytical Treatment Interruptions in Chronic HIV-1-Infected Patients. Open
 519 Forum Infectious Diseases. 1 déc 2019;6(12):ofz485.
- 520 18. Graziani GM, Angel JB. Evaluating the efficacy of therapeutic HIV vaccines through analytical
 521 treatment interruptions. Journal of the International AIDS Society. 2015;18(1):20497.
- Treasure GC, Aga E, Bosch RJ, Mellors JW, Kuritzkes DR, Para M, et al. Relationship Among Viral
 Load Outcomes in HIV Treatment Interruption Trials. J Acquir Immune Defic Syndr. 1 juill
 2016;72(3):31023.
- 525 20. Zheng L, Tierney C, Bosch RJ. Analytical Treatment Interruption in HIV Trials: Statistical and Study
 526 Design Considerations. Curr HIV/AIDS Rep. 1 oct 2021;18(5):475282.
- Lau JSY, Smith MZ, Lewin SR, McMahon JH. Clinical trials of antiretroviral treatment interruption
 in HIV-infected individuals. AIDS. 1 avr 2019;33(5):773.
- 529 22. Lévy Y, Lacabaratz C, Lhomme E, Wiedemann A, Bauduin C, Fenwick C, et al. A Randomized
 530 Placebo-Controlled Efficacy Study of a Prime Boost Therapeutic Vaccination Strategy in HIV-1 531 Infected Individuals: VRIO2 ANRS 149 LIGHT Phase II Trial. Journal of Virology. 12 avr
 532 2021;95(9):10.1128/jvi.02165-20.
- 533 23. Cobb A, Roberts LK, Palucka AK, Mead H, Montes M, Ranganathan R, et al. Development of a HIV534 1 lipopeptide antigen pulsed therapeutic dendritic cell vaccine. Journal of Immunological
 535 Methods. 28 févr 2011;365(1):272 37.
- 536 24. Lévy Y, Thiébaut R, Montes M, Lacabaratz C, Sloan L, King B, et al. Dendritic cell-based
 537 therapeutic vaccine elicits polyfunctional HIV-specific T-cell immunity associated with control of
 538 viral load. 2014;9.
- 539 25. Thiébaut R, Hejblum BP, Hocini H, Bonnabau H, Skinner J, Montes M, et al. Gene Expression
 540 Signatures Associated With Immune and Virological Responses to Therapeutic Vaccination With
 541 Dendritic Cells in HIV-Infected Individuals. Front Immunol. 1 janv 2019;10:874.


542 26. Lévy Y, Thiébaut R, Gougeon ML, Molina JM, Weiss L, Girard PM, et al. Effect of intermittent
543 interleukin-2 therapy on CD4+ T-cell counts following antiretroviral cessation in patients with HIV.
544 AIDS. 27 mars 2012;26(6):711.


- 545 27. Benjamini Y, Hochberg Y. Controlling the False Discovery Rate: A Practical and Powerful Approach
 546 to Multiple Testing. Journal of the Royal Statistical Society: Series B (Methodological).
 547 1995;57(1):2892300.
- Alexandre M, Prague M, Thiébaut R. Between-group comparison of area under the curve in
 clinical trials with censored follow-up: Application to HIV therapeutic vaccines. Stat Methods
 Med Res. 1 oct 2021;30(9):2130247.
- 551 29. García F, Climent N, Guardo AC, Gil C, León A, Autran B, et al. A Dendritic Cell–Based Vaccine
 552 Elicits T Cell Responses Associated with Control of HIV-1 Replication. Science Translational
 553 Medicine. 2 janv 2013;5(166):166ra2-166ra2.
- So. Peay HL, Rennie S, Cadigan RJ, Gwaltney A, Jupimai T, Phanuphak N, et al. Attitudes About
 Analytic Treatment Interruption (ATI) in HIV Remission Trials with Different Antiretroviral Therapy
 (ART) Resumption Criteria. AIDS Behav. 1 mai 2022;26(5):1504216.
- S1. Protiere C, Arnold M, Fiorentino M, Fressard L, Lelièvre JD, Mimi M, et al. Differences in HIV cure
 clinical trial preferences of French people living with HIV and physicians in the ANRS-APSEC
 study: a discrete choice experiment. Journal of the International AIDS Society.
 2020;23(2):e25443.
- Lau JSY, Smith MZ, Allan B, Martinez C, Power J, Lewin SR, et al. Perspectives on Analytical
 Treatment Interruptions in People Living with HIV and Their Health Care Providers in the
 Landscape of HIV Cure-Focused Studies. AIDS Res Hum Retroviruses. 1 avr 2020;36(4):26027.
- 564 33. Dubé K, Agarwal H, Carter WB, Dee L, Taylor J, Roebuck C, et al. Participant experiences using
 565 novel home-based blood collection device for viral load testing in HIV cure trials with analytical
 566 treatment interruptions. HIV Research & Clinical Practice. 31 déc 2022;23(1):76290.


567






























Virological criteria	Definition			
Fixed criteria				
Peak VL [in log ₁₀ copies/mL]	The maximum VL value during ATI phase. In case of long ATI phase (e.g., in ILIADE trial), an increasing viral dynamics can be observed in some patients after the stabilization of the dynamics and reach higher values than the peak of rebound. In that case, the higher VL value observed before the stabilization was kept.			
Setpoint [in log ₁₀ copies/mL]	The mean value of VL values belonging to the first sliding window with a height of 0.5 log_{10} copies/mL, and with a width of at least 4 weeks including at least two consecutive VL values.			
Time-averaged AUC (nAUC) [in log ₁₀ copies/mL]	Area under the viral rebound curve averaged by the duration (in weeks) of ATI phase.			
Temporal criteria				
Time to rebound (TTR) [in weeks] Slope of viral rebound [in log ₁₀ copies/mL/week]	The time between ART interruption and the first detectable VL value (>40 copies/mL in LIGHT, and >50 copies/mL in ILIADE and DALIA). The slope from the last undetectable VL value to the peak VL.			
Time to peak VL [in weeks]	The time between ART interruption and the peak VL (only for patients with observed peak VL).			
Time to setpoint [in weeks]	The time between ART interruption and the first VL value belonging to the window defining the setpoint (only for patients with observed setpoint).			
Time to VL threshold [in weeks]	The time between ART interruption and the first VL value exceeding a specific VL threshold. Four different VL thresholds, commonly used in HIV vaccine trials, were considered: 200, 1 000, 10 000, and 100 000 copies/mL.			

Table 1 – Definitions of virological criteria analyzed in the study

Abbreviations: ATI, Analytical treatment interruption; VL, Viral load; ART, Antiretroviral treatment.

	LIGHT (n=87)		ILIADE (n=129)		
	Placebo (n=31)	Vaccine (n=56)	Control (n=57)	∣L2 (n=72)	DALIA (n=19)
ATI duration (weeks) Median [Min-Max]	12 [4 ; 12]	12 [2 ; 12]	48 [0 ; 48]	48 [0 ; 48]	28 [8 ; 36]
Nb VL measurements Median [Min-Max]	6 [3 ; 6]	6 [2 ; 6]	7 [1;7]	7 [2 ; 7]	11 [6 ; 13]
ATI re-start* n (%)	7 (23)	11 (20)	20 (35)	14 (19)	3 (16)

Table 2 – Description of ATI in the three therapeutic vaccine trials.

Abbreviations: ATI, Analytical treatment interruption; VL, Viral load; ART, Antiretroviral treatment. *Evaluation of the number and the percentage of patient who restart their ART before the end of ATI phase, i.e. before predefined ATI duration in LIGHT (12th week) or before time of primary endpoint in ILIADE (48th week) and DALIA (24th week).

		LIGHT (n=87)		ILIADE (n=129)		
		Placebo (n=31)	Vaccine (n=56)	Control (n=57)	IL2 (n=72)	DALIA (n=19)
			Fixed criteria			
Peak VL	N (%)	31 (100)	56 (100)	55 (96)	72 (100)	19 (100)
log10 cp/mL	Median [IQR]	4.97 [4.53 ; 5.74]	4.92 [4.62 ; 5.34]	4.94 [4.29 ; 5.05]	4.68 [4.20 ; 4.99]	4.94 [4.10 ; 5.18]
	P-value (1)	P =	0.96	P =	0.98	
Setpoint	N(%)	19 (61)	28 (50)	48 (84)	63 (88)	18 (95)
log10 cp/mL	Median [IQR]	4.32 [3.97 ; 4.78]	4.62 [4.42 ; 4.93]	4.46 [4.00 ; 4.86]	4.42 [3.96 ; 4.71]	4.15 [3.92 ; 4.74]
	P-value ⁽¹⁾	P = 0.73		P = 0.98		
nAUC	N (%)	31 (100)	56 (100)	55 (95)	72 (100)	19 (100)
log10 cp/mL	Median [IQR]	3.73 [3.28 ; 4.18]	3.74 [3.25 ; 4.20]	4.14 [3.75 ; 4.43]	4.11 [3.63 ; 4.39]	4.00 [3.68 ; 4.29]
	P-value (1)	P =	0.96	P =	0.98	
			Temporal criteria			
Time to rebound	N (%)	30 (97)	53 (95)	54 (95)	71 (99)	19 (100)
Weeks	Median [IQR]	2 [2 ; 4]	2 [2 ; 4]	8 [8 ; 8]	8 [8 ; 8]	3 [2 ; 6]
	P-value (1)	P =	0.96	P = 0.65		
Slope rebound	N (%)	30 (97)	53 (95)	54 (94)	71 (99)	19 (100)
log10 cp/mL/week	Median [IQR]	0.80 [0.56 ; 1.08]	0.75 [0.59 ; 1.04]	0.29 [0.16 ; 0.36]	0.27 [0.18 ; 0.36]	0.52 [0.36 ; 0.89]
	P-value ⁽¹⁾	P =	0.96	P =	0.98	
Time to peak VL	N (%)	31 (100)	56 (100)	55 (96)	72 (100)	19 (100)
Weeks	Median [IQR]	6 [4 ; 6]	6 [4 ; 6.5]	8 [8 ; 16]	8 [8 ; 16]	8 [4 ; 12]
	P-value ⁽¹⁾	P = 0.96		P = 0.98		
Time to setpoint	N (%)	19 (61)	28 (50)	48 (84)	63 (88)	18 (95)
Weeks	Median [IQR]	8 [6 ; 8]	6 [4 ; 8]	16 [8 ; 24]	16 [8 ; 24]	10 [8 ; 15]
	P-value ⁽¹⁾	P = 0.73		P = 0.98		
Time to 200 cp/mL	N (%)	30 (97)	52 (93)	54 (95)	72 (100)	19 (100)
Weeks	Median [IQR]	4 [2 ; 4]	4 [2;4]	8 [8 ; 8]	8 [8 ; 8]	3 [3 ; 8]
	P-value (1)	P = 0.96		P = 0.79		
Time to 1000 cp/mL	N (%)	28 (90)	52 (93)	51 (89)	70 (97)	18 (95)
Weeks	Median [IQR]	4 [2 ; 4]	4 [2;4]	8 [8 ; 8]	8 [8 ; 8]	4 [3 ; 8]
	P-value (1)	P =	0.96	P =	0.55	
Time to 10000 cp/mL	N (%)	27 (87)	51 (91)	48 (84)	59 (82)	18 (95)
Weeks	Median [IQR]	4 [4 ; 6]	4 [4 ; 6]	8 [8 ; 8]	8 [8 ; 8]	8 [4 ; 12]
	P-value (1)	P =	0.96	P =	0.65	
Time to 1e5 cp/mL	N (%)	15 (48)	27 (48)	19 (33)	20 (28)	10 (53)
Weeks	Median [IQR]	4 [4 ; 5]	6 [4 ; 6]	16 [8 ; 16]	16 [8 ; 16]	8 [5 ; 12]
	P-value (1)	P =	0.73		0.98	

Table 3 - Distribution of the different virological criteria estimated in the three therapeutic vaccine trials.

Abbreviations: ATI, Analytical treatment interruption ; IQR, Interquartile range; AUC, Area under the curve; VL, Viral load.

"n" indicates the total number of cases, "N" indicates the number of cases with observed endpoints in each group.

⁽¹⁾ P-values of pairwise comparisons (Mann-Whitney U test) in the different trials between therapeutic and control groups.